Owkin

Co-founded in 2016 by Thomas Clozel, oncologist, and Gilles Wainrib, Professor of Artificial Intelligence, OWKIN develops innovative services and solutions to accelerate the discovery of new treatments and advance personalized medicine. The growing accumulation of data, combined with the recent revolution in artificial intelligence, makes it possible to discover new therapeutic targets, to predict the effect of molecules and to help doctors give the right treatment to the right person. At the heart of the medicine of the future, OWKIN counts among its customers and partners pharmaceutical companies, hospitals specializing in the treatment of cancer like the Institut Curie, and academic research laboratories, in France and abroad.